Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2023-09-28 Purchase | 2023-10-02 4:39 pm | Transcode Therapeutics Inc. | RNAZ | Fitzgerald Thomas A Chief Financial Officer | 49,350 | $0.51 | $25,169 | 56,318 (Direct) | View |
| 2023-09-28 Purchase | 2023-10-02 4:37 pm | Transcode Therapeutics Inc. | RNAZ | Dudley Robert Michael Chief Executive Officer | 98,000 | $0.51 | $49,980 | 180,262 (Direct) | View |
| 2023-06-20 Purchase | 2023-06-22 6:23 pm | Transcode Therapeutics Inc. | RNAZ | Dudley Robert Michael Chief Executive Officer | 18,607 | $2.6154 | $48,665 | 82,262 (Direct) | View |
| 2023-06-09 Purchase(A) | 2023-06-14 4:16 pm | Transcode Therapeutics Inc. | RNAZ | Dudley Robert Michael Chief Executive Officer | 19,000 | $2.76 | $52,440 | 61,155 (Direct) | View |
| 2023-06-09 Purchase | 2023-06-13 4:16 pm | Transcode Therapeutics Inc. | RNAZ | Dudley Robert Michael Chief Executive Officer | 19,000 | $2.76 | $52,440 | 912,114 (Direct) | View |
| 2022-09-14 Purchase | 2022-09-16 6:44 pm | Transcode Therapeutics Inc. | RNAZ | Dudley Robert Michael Chief Executive Officer 10% Owner | 20,000 | $1.15 | $23,000 | 893,114 (Direct) | View |
| 2022-06-16 Purchase | 2022-06-17 4:01 pm | Transcode Therapeutics Inc. | RNAZ | Fitzgerald Thomas A Chief Financial Officer | 12,000 | $1.27 | $15,240 | 139,377 (Direct) | View |
| 2022-05-27 Purchase | 2022-06-01 4:01 pm | Transcode Therapeutics Inc. | RNAZ | Dudley Robert Michael Chief Executive Officer 10% Owner | 30,000 | $1.8461 | $55,383 | 873,114 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-06-14 Option Award | 2024-06-18 4:16 pm | N/A 2034-06-13 | Transcode Therapeutics Inc. | RNAZ | Marquet Magda Director | 70,000 | $0 | 70,000 (Direct) | View |
| 2024-06-14 Option Award | 2024-06-18 4:16 pm | N/A 2034-06-13 | Transcode Therapeutics Inc. | RNAZ | Manting Erik Director | 70,000 | $0 | 70,000 (Direct) | View |
| 2024-06-14 Option Award | 2024-06-18 4:15 pm | N/A 2034-06-13 | Transcode Therapeutics Inc. | RNAZ | Fitzgerald Thomas A Interim CEO, CFO | 650,000 | $0 | 650,000 (Direct) | View |
| 2024-06-14 Option Award | 2024-06-18 4:15 pm | N/A 2034-06-13 | Transcode Therapeutics Inc. | RNAZ | Calais Philippe Director | 70,000 | $0 | 70,000 (Direct) | View |
| 2023-05-19 Option Award | 2023-05-19 8:09 pm | N/A 2033-05-18 | Transcode Therapeutics Inc. | RNAZ | Manting Erik Director | 45,000 | $0 | 45,000 (Direct) | View |
| 2023-05-19 Option Award | 2023-05-19 8:08 pm | N/A 2033-05-18 | Transcode Therapeutics Inc. | RNAZ | Marquet Magda Director | 45,000 | $0 | 45,000 (Direct) | View |
| 2023-05-19 Option Award | 2023-05-19 8:07 pm | N/A 2033-05-18 | Transcode Therapeutics Inc. | RNAZ | Fitzgerald Thomas A Chief Financial Officer | 300,000 | $0 | 300,000 (Direct) | View |
| 2023-05-19 Option Award | 2023-05-19 8:06 pm | N/A 2033-05-18 | Transcode Therapeutics Inc. | RNAZ | Dudley Robert Michael Chief Executive Officer | 735,000 | $0 | 735,000 (Direct) | View |
| 2023-05-19 Option Award | 2023-05-19 8:06 pm | N/A 2033-05-18 | Transcode Therapeutics Inc. | RNAZ | Calais Philippe Director | 45,000 | $0 | 45,000 (Direct) | View |
| 2023-05-10 Option Award | 2023-05-10 6:13 pm | N/A 2033-05-09 | Transcode Therapeutics Inc. | RNAZ | Manting Erik Director | 9,500 | $0 | 9,500 (Direct) | View |
| 2023-05-10 Option Award | 2023-05-10 6:12 pm | N/A 2033-05-09 | Transcode Therapeutics Inc. | RNAZ | Marquet Magda Director | 9,500 | $0 | 9,500 (Direct) | View |
| 2023-05-10 Option Award | 2023-05-10 6:10 pm | N/A 2033-05-09 | Transcode Therapeutics Inc. | RNAZ | Calais Philippe Director | 9,500 | $0 | 9,500 (Direct) | View |
| 2022-12-12 Option Award | 2022-12-14 8:13 pm | N/A 2032-12-11 | Transcode Therapeutics Inc. | RNAZ | Fitzgerald Thomas A Chief Financial Officer | 100,000 | $0 | 100,000 (Direct) | View |
| 2022-12-12 Option Award | 2022-12-14 8:11 pm | N/A 2032-12-11 | Transcode Therapeutics Inc. | RNAZ | Dudley Robert Michael Chief Executive Officer 10% Owner | 135,000 | $0 | 135,000 (Direct) | View |
| 2022-12-12 Option Award | 2022-12-14 8:10 pm | N/A 2027-12-11 | Transcode Therapeutics Inc. | RNAZ | Medarova Zdravka Chief Technology Officer 10% Owner | 60,000 | $0 | 60,000 (Direct) | View |
| 2022-02-01 Option Award | 2022-12-14 8:06 pm | N/A 2027-01-31 | Transcode Therapeutics Inc. | RNAZ | Medarova Zdravka Chief Technology Officer 10% Owner | 33,000 | $0 | 33,000 (Direct) | View |
| 2022-06-22 Option Award | 2022-06-22 8:27 pm | N/A 2032-06-21 | Transcode Therapeutics Inc. | RNAZ | Calais Philippe Director | 9,500 | $0 | 9,500 (Direct) | View |
| 2022-06-22 Option Award | 2022-06-22 8:25 pm | N/A 2032-06-21 | Transcode Therapeutics Inc. | RNAZ | Marquet Magda Director | 9,500 | $0 | 9,500 (Direct) | View |
| 2022-06-22 Option Award | 2022-06-22 8:24 pm | N/A 2032-06-21 | Transcode Therapeutics Inc. | RNAZ | Manting Erik Director | 9,500 | $0 | 9,500 (Direct) | View |
| 2022-03-01 Option Award | 2022-03-02 6:12 pm | N/A 2032-02-29 | Transcode Therapeutics Inc. | RNAZ | Fitzgerald Thomas A Chief Financial Officer | 52,000 | $0 | 52,000 (Direct) | View |
| 2022-02-01 Option Award | 2022-02-03 06:04 am | N/A 2031-01-31 | Transcode Therapeutics Inc. | RNAZ | Fitzgerald Thomas A Chief Financial Officer | 33,000 | $0 | 33,000 (Direct) | View |
| 2022-02-01 Option Award | 2022-02-03 06:03 am | N/A 2031-01-31 | Transcode Therapeutics Inc. | RNAZ | Dudley Robert Michael Chief Executive Officer 10% Owner | 135,000 | $0 | 135,000 (Direct) | View |
Ownership | 2021-07-08 9:54 pm | N/A N/A | Transcode Therapeutics Inc. | RNAZ | Dudley Robert Michael Chief Executive Officer 10% Owner | 0 | $0 | 1,661,965 (Direct) | View |
Ownership | 2021-07-08 9:53 pm | N/A N/A | Transcode Therapeutics Inc. | RNAZ | Fitzgerald Thomas A VP, Chief Financial Officer | 0 | $0 | 369,999 (Direct) | View |
Ownership | 2021-07-08 9:53 pm | N/A N/A | Transcode Therapeutics Inc. | RNAZ | Medarova Zdravka 10% Owner | 0 | $0 | 1,674,096 (Direct) | View |
Ownership | 2021-07-08 9:53 pm | N/A 2030-12-01 | Transcode Therapeutics Inc. | RNAZ | Manting Erik Director | 0 | $0 | 36,393 (Direct) | View |
Ownership | 2021-07-08 9:53 pm | N/A N/A | Transcode Therapeutics Inc. | RNAZ | Calais Philippe Director | 0 | $0 | 163,770 (Direct) | View |
Ownership | 2021-07-08 9:52 pm | N/A N/A | Transcode Therapeutics Inc. | RNAZ | Moore Anna 10% Owner | 0 | $0 | 1,613,440 (Direct) | View |
Ownership | 2021-07-08 9:52 pm | N/A 2031-01-05 | Transcode Therapeutics Inc. | RNAZ | Marquet Magda Director | 0 | $0 | 36,393 (Direct) | View |